Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB/miR-155-5p inflammatory loop

doi:10.4239/wjd.v12.i1.19

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9230)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-12) series, Tables (1-6) series.

Item

Count

PDF

524

WORD

298

HTML

5147

Figures (1-12)

412

Tables (1-6)

353

Sum=6734

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

385

Download

780

Sum=1165

Publishing Process of This Article

Item

Count

Browse

514

Download

817

Sum=1331

Jan 15, 2021 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (42)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Jan 15, 2021; 12(1): 19-46
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.19

Table 1 Sequences of siRNAs used for transfection

Gene	Sequence
TNC-siRNA	siRNA-TNC-T1 sense	5’-GCA UCU GUG AUG AUG ACU ATT-3’
	Anti-sense	5’-UAG UCA UCA UCA CAG AUG CTT-3’
	siRNA-TNC-T2 sense	5’-GCU GAG AAG GGC AGA CAU ATT-3’
	Anti-sense	5’-UAU GUC UGC CCU UCU CAG CTT-3’
	siRNA-TNC-T3 sense	5’-GCA UUU GUG AGG AUG GUU UTT-3’
	Anti-sense	5’-AAA CCA UCC UCA CAA AUG CTT-3’
	NC-siRNA-T	5’-UUC UCC GAA CGU GUC ACG UTT-3’
	Anti-sense	5’-ACG UGA CAC GUU CGG AGA ATT-3’
TLR4-siRNA	siRNA-TLR4	5’-CGA GCU GGU AAA GAA UUU ATT-3’
	Anti-sense	5’-UAA AUU CUU UAC CAG CUC GTT-3’
	NC-siRNA-TLR4 sense	5’-UUC UCC GAA CGU GUC ACG UTT-3’
	Anti-sense	5’-ACG UGA CAC GUU CGG AGA ATT-3’
miR-155-5p inhibitor	Inhibitor	5’-ACC CCU AUC ACA AUU AGC AUU AA-3’
	Inhibitor-NC	5’-CAG UAC UUU UGU GUA GUA CAA-3’

TNC: Tenascin-C; TLR4: Toll-like receptor-4; NC: Normal control.

Table 2 Comparison of clinical characteristics and biochemical data among groups [mean ± SEM, M (quartile)]

Group	n	Age (yr)	TG (mmol/L)	TC (mmol/L)	LDL-C (mmol/L)	HDL-C (mmol/L)	UA (μmol/L)	HbA1C (%)	TNC (pg/mL)	UACR (mg/g)	SBP (mmHg)	DBP (mmHg)	HOMA-IR
A	60	50 ± 1.29	1.17 (0.92-1.48)	4.58 ± 0.11	2.80 ± 0.11	1.44 ± 0.05	279.54 ± 8.43	5.40 (5.25-5.70)	15.20 (14.08-15.95)	9.92 (7.58-11.23)	119 ± 1.55	72 ± 1.29	1.02 ± 0.08
B	70	52 ± 1.79	0.91 (0.71-1.59)	5.13 ± 0.15	3.40 ± 0.14	1.29 ± 0.04	265.77 ± 7.08	7.30 (6.05-8.70)^a	15.07 (12.10-17.95)	16.76 (13.58-24.26)^a	118 ± 1.79	74 ± 0.84	2.53 ± 0.12^a
C	105	56 ± 1.07	2.07 (1.32-3.01)^a^,^b	4.62 ± 0.07	2.88 ± 0.06	1.12 ± 0.03^a	340.24 ± 8.17^a^,^b	8.40 (7.50-9.80)^a	17.07 (14.70-19.88)^a^,^b	44.85 (33.91-59.59)^a^,^b	126 ± 0.68	77 ± 0.68	4.68 ± 0.26^a^,^b
D	75	57 ± 1.5	1.84 (1.55-3.87)^a^,^b	4.49 ± 0.13	2.89 ± 0.11	1.00 ± 0.02^a^,^b	348.87 ± 10.83^a^,^b	7.30 (6.60-8.50)^a	18.96 (14.70-21.40)^a^,^b^,^c	56.17 (45.80-159.74)^a^,^b^,^c	152 ± 1.04^a^,^b^,^c	92 ± 1.5^a^,^b^,^c	4.85 ± 0.34^a^,^b
E	65	52 ± 0.99	2.08 (1.76-2.88)^a^,^b	5.61 ± 0.16^a^,^c^,^d	3.68 ± 0.13^a^,^c^,^d	1.21 ± 0.03	381.11 ± 10.47^a^,^b	7.80 (7.00-9.25)^a	18.71 (16.40-19.95)^a^,^b^,^c	871.58 (390.94-871.58)^a^,^b^,^c^,^d	127 ± 1.36	79 ± 0.99	5.65 ± 0.45^a^,^b
F	65	59 ± 1.36	1.99 (1.38-4.07)^a^,^b	4.84 ± 0.15	2.84 ± 0.12^e	1.11 ± 0.04^a	358.38 ± 8.27^a^,^b	9.10 (7.10-9.70)^a	21.16 (16.92-21.35)^a^,^b^,^c^,^d^,^e	1094.62 (790.00-5246.40)^a^,^b^,^c^,^d^,^e	160 ± 1.49^a^,^b^,^c^,^e	96 ± 1.86^a^,^b^,^c^,^e	5.75 ± 0.4^a^,^b

^aP < 0.05 compared with group A.

^bP < 0.05 compared with group B.

^cP < 0.05 compared with group C.

^dP < 0.05 compared with group D.

^eP < 0.05 compared with group E. 1 mmHg = 0.133 kPa; A: Healthy group; B: Normal albuminuria group; C: Microalbuminuria group; D: Microalbuminuria combined with hypertension group; E: Macroalbuminuria group; F: Macroalbuminuria combined with hypertension group. BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; UACR: Urinary albumin to creatinine ratio; HOMA-IR: Homeostasis model assessment-insulin resistance; HOMA-IR: Homeostasis model assessment of insulin resistance, = FRG × FINS / 22.5; HDL-C: High-density lipoprotein-cholesterol; LDL-C: Low-density lipoprotein-cholesterol; TC: Total cholesterol; TG: Triglycerides; UA: Uric acid; TNC: Tenascin-C.

Table 3 Correlation between tenascin-C levels and urinary albumin excretion rate

Index	lgTNC
Index	β	t	P value
Constant	0.0001	-31.965	0.001
lgHbA_1c	0.405	15.893	0.001
BMI	0.110	4.090	0.002
SBP	0.341	13.379	0.002
lgUACR	0.131	4.621	0.001

BMI: Body mass index; SBP: Systolic blood pressure; 1 mmHg = 0.133 kPa; UACR: Urinary albumin to creatinine ratio; TNC: Tenascin-C.

Table 4 Comparison of expression of tenascin-C, creatinine, and urea nitrogen in serum of rats [mean ± SD, M (quartile)]

Group	n	TNC (ng/mL)	Creatinine (mmol/L)	Urea nitrogen (mmol/L)
N	6	40.85 ± 2.99	37.27 ± 6.41	6.02 ± 1.57
D	6	59.25 ± 3.46^a	129.08 ± 39.88^a	22.48 ± 2.71

^aP < 0.05 compared with group. N, n = 6 for each group. N: Normal rat serum; D: Diabetic rat serum; TNC: Tenascin-C.

Table 5 Comparison of expression of tenascin-C in the supernatant of rat mesangial cell culture [mean ± SD, M (quartile)]

Group	n	TNC (ng/mL)
Ns	6	57.43 ± 5.94
Hs	6	70.13 ± 2.84^a

^aP < 0.05 compared with group Ns, n = 6 for each group. Ns: Normal condition supernatant (NG, 5.5 mmol/L glucose). Hs: High-glucose condition supernatant (HG, 30 mmol/L glucose).

Table 6 Real-time polymerase chain reaction primer sequences

Primer	Sequence
miR-155-5p	Forward	5’-GGT GCG GTT AAT GCT AAT TGT G-3’
	Reverse	5’-CAG AGC AGG GTC CGA GGTA-3’
U6	Forward	5’-CGC TTC GGC AGC ACA TAT AC-3’
	Reverse	5’-TTC ACG AAT TTG CGT GTC ATC-3’

Citation: Zhou Y, Ma XY, Han JY, Yang M, Lv C, Shao Y, Wang YL, Kang JY, Wang QY. Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB/miR-155-5p inflammatory loop. World J Diabetes 2021; 12(1): 19-46
URL: https://www.wjgnet.com/1948-9358/full/v12/i1/19.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i1.19